FrancophonIA/ELRC3.0 huggingface dataset:
English: Collagen hydrolysate Casein hydrolysate Sodium chloride
Slovenian: Hidrolizat kolagena Hidrolizat kazeina Natrijev klorid
English: Moreover feline IL-2 has been shown to have very low biological activity on human leukocytes compared to human IL-2.
Slovenian: Še več, mačji IL-2 ima v primerjavi s človeški IL-2 dokazano zelo nizko biološko aktivnost na človeške levkocite.
English: Efficacy has not been tested in cats with metastasis or lymph node involvement.
Slovenian: Učinkovitost ni bila preskušena pri mačkah z metastazami ali razširjenostjo bolezni na bezgavke.
English: After two years of study follow-up, Oncept IL-2 treated cats showed a longer median time to relapse (above 730 days) compared to control cats (287 days).
Slovenian: Po dveh letih po študiji, je bil povprečni čas do ponovitve bolezni pri mačkah, zdravljenih z Oncept IL-2, daljši (nad 730 dni) v primerjavi s kontrolno skupino (287 dni).
English: After reconstitution of the lyophilisate with the solvent, shake gently and administer five injections (each approximately 0.2 ml) around the tumour excision site: one injection at each corner and one injection at the centre of a 5 cm x 5 cm square centred on the middle of the surgical scar.
Slovenian: Po rekonstituciji liofilizata z vehiklom nežno pretresite in okrog mesta odstranitve tumorja 5-krat injicirajte zdravilo (po približno 0,2 ml); ena injekcija v vsakem kotu in ena injekcija na v centru 5 cm x 5 cm velikega kvadrata, lociranega na sredino kirurške brazgotine.
English: EXP {month/year} Use immediately after reconstitution.
Slovenian: EXP {mesec/leto} Po rekonstituciji uporabite takoj.
English: Lyophilisate: 6 x 1 dose Solvent: 6 x 1 ml
Slovenian: Liofilizat 6 x 1 odmerek Vehikel 6 x 1 ml
English: Name and address of the manufacturer of the biological active substance
Slovenian: Ime in naslov proizvajalcev biološke učinkovine
English: Solvent: Water for injections.
Slovenian: Vehikel: Voda za injiciranje
English: Disodium phosphate dihydrate Potassium dihydrogen phosphate.
Slovenian: Natrijev dihidrogenfosfat dihidrat Kalijev dihidrogenfosfat
English: A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Slovenian: Zato se za uporabo tega imunološkega zdravila pred ali po uporabi katerega koli drugega zdravila za uporabo v veterinarski medicini odločamo od primera od primera.
English: Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, other immunostimulants.
Slovenian: Farmakoterapevtska skupina: Zdravila z delovanjem na novotvorbe in imunomodulatorji, druga zdravila za spodbujanje imunske odzivnosti.
English: Specific mechanisms by which immunostimulation induces anti-tumoural activity is not known.
Slovenian: Specifični mehanizmi s katerimi imunostimulacija inducira protitumorsko delovanje, niso znani.
English: Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.
Slovenian: Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini, razen z vehiklom, ki je priložen za uporabo s tem zdravilom za uporabo v veterinarski medicini.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Slovenian: Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini.
English: Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis).
Slovenian: Imunoterapija kot dodatna terapija operativnimu zdravljenjemu in radioterapiji pri mačkah s fibrosarkomom (2-5 cm v premeru) brez metastaz ali prizadetosti bezgavk, da se za zmanjša nevarnost povrnitve bolezni in podaljša časa do povrnitve bolezni (lokalna ponovitev ali metastaza).
English: Overdose (symptoms, emergency procedures, antidotes):
Slovenian: Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno):
English: Oncept IL-2 injected into the tumour bed thus delivers in situ a low dose of feline interleukin-2, which stimulates antitumour immunity while avoiding toxicity associated with systemic treatment.
Slovenian: Oncept IL-2 tako zagotovi in situ nizek odmerek mačjega interleukina-2, ki stimulira protitumorsko imunost ter brez toksičnosti, ki je lahko posledica sistemskega dajanja.
English: Store in the original package in order to protect from light.
Slovenian: Zaščitite pred svetlobo.
English: SC Read the package leaflet before use.
Slovenian: SC Pred uporabo preberite navodilo za uporabo.
English: Oncept IL-2 treatment reduced the risk of relapse, from 6 months after the start of treatment, by approximately 56% after 1 year and 65% after 2 years.
Slovenian: 6 esecev po začetku zdravljenja za približno 56% po 1 letu in 65% po dveh letih.
English: After reconstitution use immediately.
Slovenian: Uporabite takoj po rekonstituciji.
English: The vaccine strain vCP1338 is a recombinant canarypox virus expressing feline interleukin-2 (IL-2).
Slovenian: Cepni sev vCP1338 je rekombinantni poxvirus kanarčkov, ki izraža mačji interleukin-2 (IL-2).
English: Oncept IL-2 lyophilisate
Slovenian: Oncept IL-2 Liofilizat
English: For the full list of excipients, see section 6.1.
Slovenian: *ELISA infektivni odmerek 50% Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
English: A moderate local reaction (pain on palpation, swelling, scratching) occurred very commonly in safety studies.
Slovenian: Zelo pogosto se je v študijah varnosti pojavila zmerna lokalna reakcija (bolečina na otip, oteklina in srbenje).
English: After the administration of an overdose (10 doses), transient moderate to marked hyperthermia, as well as local reactions (swelling, erythema or slight pain, and in some cases, heat at the injection site) may occur.
Slovenian: Po dajanju prevelikega odmerka (10 odmerkov), se lahko pojavijo prehodno zmerno do močneje povišana telesna temperatura, lahko pa tudi lokalne reakcije (oteklina, eritem ali rahla bolečina in v nekaterih primerih toplota na mestu injiciranja).
English: Oncept IL-2 lyophilisate and solvent for suspension for injection for cats
Slovenian: Oncept IL-2 liofilizat in vehikel za suspenzijo za injiciranje za mačke
English: Efficacy has only been tested in conjunction with surgery and radiotherapy; therefore the treatment should be conducted according to treatment course described in section “Dosage for each species, route and method of administration”.
Slovenian: Učinkovitost je bila preskušena le v povezavi z operativnim zdravljenjem in radioterapijo, zato je potrebno zdraviti v skladu s potekom zdravljenja, ki je opisan v poglavju « ODMERKI ZA
English: Use of the recommended mode of administration in 5 injection points is important for achieving efficacy of the product; injection in 1 point may lead to reduced efficacy (see section 4.9).
Slovenian: pri injiciranju na enem mestu lahko pride do manjše učinkovitosti (glejte poglavje 4.9).
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box of 6 vials of lyophilisate and 6 vials of solvent
Slovenian: PODATKI NA ZUNANJI OVOJNINI Škatla s 6 vialami liofilizata in 6 vialami vehikla
English: Solvent for Oncept IL-2
Slovenian: Vehikel za Oncept IL-2
English: Transient apathy and hyperthermia (above 39.5 °C) occurred commonly in field studies.
Slovenian: Lahko se pojavita prehodna apatija in povišana telesna temperatura (nad 39° C).
English: Name and address of the manufacturer responsible for batch release
Slovenian: Ime in naslov proizvajalcazdravila odgovornega za sproščanje serije
English: Cardboard box containing 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent.
Slovenian: Škatla s 6 vialami liofilizata in 6 vialami vehikla.
English: In a randomized clinical study, cats from different origins presenting a fibrosarcoma without metastasis or lymph node involvement were included in two groups, one receiving the reference treatment - surgery and radiotherapy - and the other receiving Oncept IL-2 in addition to surgery and radiotherapy.
Slovenian: V klinični študiji so bile mačke različnega izvora s fibrosarkomom brez metastaz in prizadetosti limfnih žlez, razdeljene v dve skupini.
English: Type I glass vial with a butyl elastomer closure, sealed with an aluminium cap. Cardboard box of 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent.
Slovenian: Viala iz stekla tipa I z butilelastomerno zaporko, zapečateno z aluminijastim pokrovčkom.
English: Feline interleukin-2 recombinant canarypox virus (vCP1338) ........................................ ≥ 106.0 EAID50
Slovenian: Rekombinantni pox virus kanarčkov (vCP1338), ki vsebuje mačji interleukin-2.............≥ 106.0 EAID*50
English: A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Slovenian: PRILOGA II A. PROIZVAJALCI BIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA,
English: QUANTITY OF THE ACTIVE SUBSTANCE(S)
Slovenian: C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
English: Lyophilisate and solvent for suspension for injection
Slovenian: liofilizat in vehikel za suspenzijo za injiciranje za mačke
English: Active substance:
Slovenian: KOLIČINA UČINKOVINE
English: However, the low number of patients involved and other serious shortcomings in the design of the studies prevented any firm conclusions being drawn.
Slovenian: Vendar zaradi nizkega števila vključenih bolnikov in drugih resnih pomanjkljivosti pri zasnovi študij ni bilo možno sprejeti trdnih zaključkov.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20 September 2016 EMA/275240/2014
Slovenian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20.
English: Passion flower EMA/275240/2014
Slovenian: Zel zdravilne pasijonke EMA/275240/2014
English: Passion flower medicines should only be used in adults and adolescents over the age of 12 years.
Slovenian: Zdravila, ki vsebujejo zel zdravilne pasijonke, se smejo uporabljati samo pri odraslih in mladostnikih, starejših od 12 let.
English: This summary is not intended to provide practical advice on how to use medicines containing passion flower.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo zel zdravilne pasijonke.
English: Passion flower is the common name for the above-ground parts of the plant Passiflora incarnata L. The HMPC conclusions only cover passion flower preparations which are obtained by comminuting (reducing into tiny pieces) or powdering the dried above-ground parts or as dry and liquid extracts.
Slovenian: Zel zdravilne pasijonke je splošno ime za nadzemne dele rastline Passiflora incarnata L. Zaključki odbora HMPC zajemajo samo pripravke z zeljo zdravilne pasijonke, ki se pridobivajo z drobljenjem (zmanjševanjem na majhne delce) ali z drobljenjem posušenih nadzemnih delov v prah ter kot suhi ali tekoči ekstrakti.
English: Further information on the risks associated with these passion flower medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Slovenian: Dodatne informacije o tveganjih, povezanih s temi zdravili, ki vsebujejo zel zdravilne pasijonke, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Herbal medicines containing these passion flower preparations are usually available as herbal teas to be drunk or as solid or liquid forms to be taken by mouth.
Slovenian: Zdravila rastlinskega izvora, ki vsebujejo te pripravke z zeljo zdravilne pasijonke, so navadno na voljo kot zdravilni čaji, ki se popijejo, ali v tekoči ali trdni obliki za jemanje skozi usta.
English: The HMPC concluded that, on the basis of its long-standing use, these passion flower preparations can be used for the relief of mild symptoms of mental stress and to aid sleep.
Slovenian: Odbor HMPC je na podlagi dolgotrajne uporabe zaključil, da se lahko ti pripravki, ki vključujejo zel zdravilne pasijonke, uporabljajo za lajšanje blagih simptomov duševne obremenitve in kot pomoč pri spanju.
English: Passion flower preparations may also be found in combination with other herbal substances in some herbal medicines.
Slovenian: Pripravki z zeljo zdravilne pasijonke so v nekaterih zdravilih rastlinskega izvora lahko na voljo tudi v kombinaciji z drugimi rastlinskimi snovmi.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of passion flower.
Slovenian: To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo zeli zdravilne pasijonke.
English: Any applications for the licensing of medicines containing passion flower have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Slovenian: Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo zel zdravilne pasijonke, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
English: Further information on the HMPC assessment of passion flower medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Slovenian: Dodatne informacije o oceni zdravil, ki vsebujejo zel zdravilne pasijonke, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: How are passion flower medicines approved in the EU?
Slovenian: Kako so zdravila, ki vsebujejo zel zdravilne pasijonke, odobrena v EU?
English: Information on the use and licensing of passion flower medicines in EU Member States should be obtained from the relevant national authorities.
Slovenian: Za informacije o uporabi in registraciji zdravil, ki vsebujejo zel zdravilne pasijonke, v državah članicah EU se obrnite na pristojni nacionalni organ.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing passion flower.
Slovenian: Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo zel zdravilne pasijonke.
English: Other information about passion flower medicines
Slovenian: Druge informacije o zdravilih, ki vsebujejo zel zdravilne pasijonke
English: The HMPC conclusions on the use of these passion flower medicines for mild symptoms of mental stress and to aid sleep are based on their ‘traditional use' in these conditions.
Slovenian: Zaključki odbora HMPC o uporabi zdravil, ki vsebujejo zel zdravilne pasijonke, za blage simptome duševne obremenitve in kot pomoč pri spanju temeljijo na njihovi „tradicionalni uporabi“.
English: In its assessment, the HMPC also considered published clinical studies of passion flower medicines.
Slovenian: V svoji oceni je odbor HMPC prav tako upošteval objavljene klinične študije zdravil, ki vsebujejo zel zdravilne pasijonke.
English: What evidence supports the use of passion flower medicines?
Slovenian: Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo zel zdravilne pasijonke?
English: Detailed instructions on how to take passion flower medicines and who can use them can be found in the package leaflet that comes with the medicine.
Slovenian: Podrobna navodila o jemanju zdravil, ki vsebujejo zel zdravilne pasijonke, in o tem, kdo sme ta zdravila jemati, so na voljo v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
English: For more information about treatment with passion flower medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravili, ki vsebujejo zel zdravilne pasijonke, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
English: What are the risks associated with passion flower medicines?
Slovenian: Kakšna tveganja so povezana z zdravili, ki vsebujejo zel zdravilne pasijonke?
English: Therefore, the HMPC conclusions on the use of passion flower medicines are based on their long-standing use.
Slovenian: Zaključki odbora HMPC v zvezi z uporabo zdravil, ki vsebujejo zel zdravilne pasijonke, zato temeljijo na njihovi dolgotrajni uporabi.
English: A doctor or a qualified healthcare practitioner should be consulted if the symptoms last for more than 2 weeks or worsen during the use of the medicine.
Slovenian: Če simptomi med uporabo zdravila trajajo več kot dva tedna ali se poslabšajo, se je
English: What is passion flower?
Slovenian: Kaj je zel zdravilne pasijonke?
English: For practical information about using passion flower medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o njihovi uporabi naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
English: To obtain a dry extract the solvent is then evaporated.
Slovenian: Topilo se nato odpari, s čimer se pridobi suhi ekstrakt.
English: Passion flower
Slovenian: Zel zdravilne pasijonke
English: The main measure of effectiveness was the response to treatment after 16 weeks.
Slovenian: Glavno merilo učinkovitosti je bil odziv na zdravljenje po 16 tednih.
English: Further information of Targretin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Targretin so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The response rates according to the 5 skin scores were 36% and 27%, respectively.
Slovenian: Stopnji odziva glede na pet kožnih karakteristik sta bili 36 % oz. 27 %.
English: Targretin (bexarotene) EMA/234177/2018
Slovenian: Targretin (beksaroten) EMA/234177/2018
English: Treatment should continue as long as the patient benefits from it.
Slovenian: Zdravljenje se nadaljuje, dokler je za bolnika koristno.
English: What measures are being taken to ensure the safe and effective use of Targretin?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Targretin?
English: Targretin (bexarotene)
Slovenian: Targretin (beksaroten)
English: The recommended starting dose is 300 mg/m2/day, taken as a single dose once a day with a meal.
Slovenian: Priporočeni začetni odmerek je 300 mg/m2/dan in se jemlje enkrat na dan pri obroku.
English: Targretin received a marketing authorisation valid throughout the EU on 29 March 2001.
Slovenian: Za zdravilo Targretin je bilo 29. marca 2001 izdano dovoljenje za promet, veljavno po vsej EU.
English: Targretin is available as capsules (75 mg).
Slovenian: Zdravilo Targretin je na voljo v obliki kapsul (75 mg).
English: The dose is adjusted depending on the patient's response to treatment or side effects.
Slovenian: Odmerek se prilagaja glede na bolnikov odziv na zdravljenje ali glede na neželene učinke.
English: As for all medicines, data on the use of Targretin are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Targretin stalno spremljajo.
English: Targretin was not compared with another medicine.
Slovenian: Zdravila Targretin niso primerjali z drugim zdravilom.
English: Other information about Targretin
Slovenian: Druge informacije o zdravilu Targretin
English: Across the two studies, among the patients who received 300 mg/m2, about half of them responded to treatment, according the doctor's grading.
Slovenian: V dveh študijah z bolniki, ki so prejemali odmerek 300 mg/m2, se jih je glede na zdravniško oceno na zdravljenje odzvala približno polovica.
English: An overview of Targretin and why it is authorised in the EU
Slovenian: Pregled zdravila Targretin in zakaj je odobreno v EU
English: Side effects reported with Targretin are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Targretin, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Sixty-one patients were treated at the starting dose of 300 mg/m2/day.
Slovenian: 61 bolnikov so zdravili z začetnim odmerkom 300 mg/m2/dan.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Targretin have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Targretin upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Targretin must not be used in women who are pregnant or breast-feeding, or women who could become pregnant and who are not using effective contraception; patients who have had pancreatitis (inflammation of the pancreas); patients with uncontrolled hypercholesterolaemia (high blood cholesterol), hypertriglyceridaemia (high blood triglycerides [fat]) or thyroid disease; patients with hypervitaminosis A (high levels of vitamin A); patients with liver disease; patients with an ongoing body infection.
Slovenian: Zdravilo Targretin se ne sme uporabljati pri nosečnicah ali doječih materah ali pri ženskah, ki bi lahko zanosile in ne uporabljajo učinkovite kontracepcije; bolnikih, ki so imeli pankreatitis (vnetje trebušne slinavke); bolnikih z nekontrolirano hiperholesterolemijo (visoka koncentracija holesterola v krvi), hipertrigliceridemijo (visoka koncentracija trigliceridov [maščob] v krvi) ali boleznijo ščitnice; bolnikih s hipervitaminozo A (visoka koncentracija vitamina A); bolnikih z boleznijo jeter; bolnikih z okužbo v telesu.
English: Ninety-three of these patients had advanced disease that had not responded to other treatment.
Slovenian: 93 bolnikov je imelo bolezen v napredovalnem stadiju, ki se ni odzvala na druga zdravljenja.
English: Why is Targretin authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Targretin odobreno v EU?
English: What benefit of Targretin have been shown in studies?
Slovenian: Kakšne koristi zdravila Targretin so se pokazale v študijah?
English: For more information about using Targretin, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Targretin glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: grading of improvement, as well as by a score of 5 clinical signs (area of skin affected, redness, raised areas, scale-like skin and colour).
Slovenian: je bil z zdravnikovo oceno izboljšanja in oceno petih kliničnih znakov (površina prizadete kože, pordelost, izbočena območja, luskasta koža in barva).
English: What are the risks associated with Targretin?
Slovenian: Kakšna tveganja so povezana z zdravilom Targretin?
English: What is Targretin and what is it used for?
Slovenian: Kaj je zdravilo Targretin in za kaj se uporablja?
English: The active substance in Targretin, bexarotene, belongs to the group of retinoids, substances that are derived from vitamin A. The exact way bexarotene works in CTCL is not known.
Slovenian: Učinkovina v zdravilu Targretin, beksaroten, spada v skupino retinoidov, snovi, ki so pridobljene iz vitamina A. Natančen način delovanja beksarotena pri kožnem T-celičnem limfomu ni znan.